What is cryptogenic organizing pneumonia, how is it diagnosed, and what is the recommended treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cryptogenic Organizing Pneumonia: Definition, Diagnosis, and Treatment

What is Cryptogenic Organizing Pneumonia?

Cryptogenic organizing pneumonia (COP) is an idiopathic interstitial lung disease characterized by fibroblast proliferation forming polypoid masses (Masson bodies) within small airways and alveolar spaces, presenting as a subacute illness that responds excellently to oral corticosteroids in the majority of patients. 1, 2

COP represents the idiopathic form of organizing pneumonia where no underlying trigger can be identified, distinguishing it from secondary organizing pneumonia associated with infections, drugs, connective tissue diseases, or malignancies. 3, 4

Clinical Presentation

Patients typically present with a subacute illness of less than 3 months duration with the following features: 3, 4, 2

  • Respiratory symptoms: Cough (often non-productive), dyspnea, and variable degrees of respiratory distress 3, 4
  • Constitutional symptoms: Fever (present in 60% of cases), myalgia, malaise, fatigue, and weight loss 3, 2, 5
  • Physical examination: Inspiratory crackles, diminished breath sounds, dull percussion, tachypnea, and tachycardia 3, 2
  • Laboratory findings: Elevated inflammatory markers (CRP, ESR) are common but nonspecific 4

A flu-like prodrome heralds the onset in approximately 40% of patients. 3

Diagnostic Approach

High-Resolution CT Imaging

HRCT is the primary imaging modality and demonstrates characteristic patterns that strongly suggest the diagnosis: 4, 2

  • Patchy, often migratory consolidation in subpleural, peribronchial, or bandlike distribution 3, 4
  • Ground-glass opacities commonly associated with consolidation 3
  • Reversed halo (atoll) sign and perilobular opacities are helpful diagnostic features when present 3, 2
  • Small pleural effusions occur in 10-30% of patients 3, 4, 6

Pulmonary Function Testing

Lung function tests characteristically show a combined restrictive and obstructive pattern with impaired gas transfer (DLCO). 2, 5

Histopathological Confirmation

Definitive diagnosis requires histopathological confirmation showing three key features: 1, 2

  1. Cellular interstitial pneumonia
  2. Cellular bronchiolitis
  3. Poorly formed nonnecrotizing granulomas

The organizing pneumonia pattern involves a patchy process with granulation tissue in alveolar ducts and alveoli, with or without bronchiolar intraluminal polyps. 3, 1 The presence of Masson bodies confirms the diagnosis and predicts excellent corticosteroid response. 1, 2

Biopsy can be obtained via:

  • Transbronchial biopsy (less invasive, adequate in some cases) 5, 7
  • Video-assisted thoracoscopic surgery (VATS) or open lung biopsy (gold standard for definitive diagnosis) 5, 7

Exclusion of Secondary Causes

Before diagnosing cryptogenic OP, systematically exclude secondary causes: 1, 4, 2

  • Infections (bacterial, viral, fungal, mycobacterial)
  • Drug reactions (chemotherapy agents, biologics, PD-1/PD-L1 inhibitors, interferon, monoclonal antibodies) 2, 8
  • Connective tissue diseases (rheumatoid arthritis, polymyositis, antisynthetase syndrome) 3, 4, 9
  • Malignancies (hematologic malignancies, solid tumors) 4, 5
  • Hypersensitivity pneumonitis 4, 2
  • Radiation therapy 8

Treatment

Oral corticosteroids are the treatment of choice for non-remitting or progressive cryptogenic organizing pneumonia. 1, 2

Corticosteroid Regimen

  • Initial dose: Prednisone approximately 50 mg/day 1, 2, 9
  • Duration: Prolonged therapy typically required for several months 5, 9
  • Response: The majority of patients recover completely with corticosteroid therapy 3, 4

Alternative Therapies

Macrolide antibiotics have been investigated but lack sufficient evidence for routine recommendation. 4 Steroid-sparing immunosuppressive agents may be considered in specific variants (cicatricial or acute fibrinous types) that require higher immunosuppression doses. 8

Prognosis and Follow-up

Complete recovery occurs in the majority of patients, but relapse is common, occurring in up to two-thirds of cases. 1, 2

Prognostic Factors

  • Five-year survival for cryptogenic OP is 73%, significantly better than secondary OP (44%) 1, 2, 9
  • Risk factors for relapse include: Fever at presentation, elevated CRP levels, and reduced DLCO % predicted 2
  • Poor prognostic variants: Some patients develop residual or progressive interstitial fibrosis despite prolonged treatment, particularly those with fibrosing variants or underlying polymyositis/antisynthetase syndrome 3, 4

Clinical Pitfalls

Maintain high clinical suspicion for COP in patients with non-resolving pneumonia who fail to respond to adequate antibiotic therapy. 6, 5 The clinical presentation often mimics community-acquired pneumonia, leading to diagnostic delays and inappropriate prolonged antibiotic use. 6, 7

Spontaneous recovery is rare; most patients require corticosteroid therapy. 7 One notable exception is focal OP presenting as an asymptomatic solitary pulmonary nodule (14% of cases), which requires no treatment and has excellent prognosis. 9

References

Guideline

Diagnostic and Treatment Considerations for Cryptogenic Organizing Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Organizing Pneumonia: Clinical Overview and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Workup and Treatment for Cryptogenic Organizing Pneumonia (COP)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Cryptogenic organizing pneumonia -- case report].

Revista portuguesa de pneumologia, 2004

Research

Update on cryptogenic organizing pneumonia.

Frontiers in medicine, 2023

Related Questions

What is the diagnosis and treatment for a patient with cryptogenic organizing pneumonia (COP) with symptoms of cough, dyspnea, and fever, and a history of possible infection, autoimmune disorders, or environmental exposures?
What are the causes and treatment options for organizing pneumonia?
What is the diagnosis and treatment for an adult patient with respiratory symptoms such as cough, dyspnea, and fever, suspected of having cryptogenic organizing pneumonia (COP)?
What are the typical presentation, diagnostic approach, and first‑line treatment for cryptogenic organizing pneumonia in adults?
What is the definition, diagnosis, signs and symptoms, pathophysiology, and treatment of Cryptogenic Organising Pneumonia (COP)?
In adult patients with solid‑tumor or hematologic malignancies and bone metastases (Category 1 indication), is denosumab (Xgeva) or zoledronic acid (Zometa) the preferred first‑line therapy, taking renal function and calcium/vitamin D supplementation into account?
Three weeks after a miscarriage, my serum human chorionic gonadotropin (hCG) is 6 mIU/mL, I have persistent red‑brown spotting, and transvaginal ultrasound shows an endometrial thickness of 8 mm; is this expected and what management is recommended?
Do benzodiazepines and oral erectile‑dysfunction medications interact with grapefruit?
Why is assessing pain disparities among racial and ethnic minorities important?
What is the appropriate treatment for a sterile inflamed subcutaneous testosterone injection site?
Why is rosuvastatin safe to take with grapefruit juice whereas other statins (e.g., simvastatin, lovastatin, atorvastatin) are not?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.